Literature DB >> 12762816

Isolation of homodolastatin 16, a new cyclic depsipeptide from a Kenyan collection of Lyngbya majuscula.

Michael T Davies-Coleman1, Thomas M Dzeha, Christopher A Gray, Sonja Hess, Lewis K Pannell, Denver T Hendricks, Catherine E Arendse.   

Abstract

An examination of an organic extract of the cyanobacterium Lyngbya majuscula, collected from Wasini Island off the southern Kenyan coast, led to the isolation of the known cyclic depsipeptide antanapeptin A (1), recently isolated from a Madagascan collection of L. majuscula, and a new bioactive cyclic depsipeptide, homodolastatin 16 (2). The structures of these two compounds were determined from NMR and mass spectrometry data. Homodolastatin 16, a higher homologue of the potential anticancer agent dolastatin 16, exhibited moderate activity against oesophageal and cervical cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12762816     DOI: 10.1021/np030014t

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  18 in total

1.  Veraguamides A-G, cyclic hexadepsipeptides from a dolastatin 16-producing cyanobacterium Symploca cf. hydnoides from Guam.

Authors:  Lilibeth A Salvador; Jason S Biggs; Valerie J Paul; Hendrik Luesch
Journal:  J Nat Prod       Date:  2011-03-29       Impact factor: 4.050

2.  Porpoisamides A and B, two novel epimeric cyclic depsipeptides from a Florida Keys collection of Lyngbya sp.

Authors:  Theresa Meickle; Sarath P Gunasekera; Yanxia Liu; Hendrik Luesch; Valerie J Paul
Journal:  Bioorg Med Chem       Date:  2011-06-06       Impact factor: 3.641

Review 3.  Marine natural product peptides with therapeutic potential: Chemistry, biosynthesis, and pharmacology.

Authors:  Vedanjali Gogineni; Mark T Hamann
Journal:  Biochim Biophys Acta Gen Subj       Date:  2017-08-24       Impact factor: 3.770

4.  Pitiprolamide, a proline-rich dolastatin 16 analogue from the marine cyanobacterium Lyngbya majuscula from Guam.

Authors:  Rana Montaser; Khalil A Abboud; Valerie J Paul; Hendrik Luesch
Journal:  J Nat Prod       Date:  2010-12-07       Impact factor: 4.050

5.  Investigation of antimicrobial and protease-inhibitory activity from cultured cyanobacteria.

Authors:  George Chlipala; Shunyan Mo; Esperanza J Carcache de Blanco; Aiko Ito; Stanley Bazarek; Jimmy Orjala
Journal:  Pharm Biol       Date:  2009-01       Impact factor: 3.503

Review 6.  Therapeutic potential of marine peptides in cervical and ovarian cancers.

Authors:  Salman Ahmed; Haroon Khan; Sajad Fakhri; Michael Aschner; Wai San Cheang
Journal:  Mol Cell Biochem       Date:  2021-12-02       Impact factor: 3.396

7.  Chirality determination of unusual amino acids using precolumn derivatization and liquid chromatography-electrospray ionization mass spectrometry.

Authors:  Sonja Hess; Kirk R Gustafson; Dennis J Milanowski; Edgardo Alvira; Mark A Lipton; Lewis K Pannell
Journal:  J Chromatogr A       Date:  2004-05-07       Impact factor: 4.759

8.  Dolastatin 15 from a Marine Cyanobacterium Suppresses HIF-1α Mediated Cancer Cell Viability and Vascularization.

Authors:  Ranjala Ratnayake; Sarath P Gunasekera; Jia Jia Ma; Long H Dang; Thomas J Carney; Valerie J Paul; Hendrik Luesch
Journal:  Chembiochem       Date:  2020-05-12       Impact factor: 3.164

Review 9.  Natural Proline-Rich Cyclopolypeptides from Marine Organisms: Chemistry, Synthetic Methodologies and Biological Status.

Authors:  Wan-Yin Fang; Rajiv Dahiya; Hua-Li Qin; Rita Mourya; Sandeep Maharaj
Journal:  Mar Drugs       Date:  2016-10-26       Impact factor: 5.118

Review 10.  Marine cyanobacteria compounds with anticancer properties: a review on the implication of apoptosis.

Authors:  Margarida Costa; João Costa-Rodrigues; Maria Helena Fernandes; Piedade Barros; Vitor Vasconcelos; Rosário Martins
Journal:  Mar Drugs       Date:  2012-09-28       Impact factor: 6.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.